Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective

BACKGROUND: Approximately 97% of global deaths due to RSV occur in low- and middle-income countries (LMICs). Until recently, the only licensed preventive intervention has been a shortacting monoclonal antibody (mAb), palivizumab (PVZ) that is expensive and intensive to administer, making it poorly s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wittenauer, Rachel, Pecenka, Clint, Baral, Ranju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067246/
https://www.ncbi.nlm.nih.gov/pubmed/37004038
http://dx.doi.org/10.1186/s12916-023-02792-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067246/
https://www.ncbi.nlm.nih.gov/pubmed/37004038
http://dx.doi.org/10.1186/s12916-023-02792-z

Ejemplares similares